October 23, 2020
We are proud to announce that @GAP_Foundation has recognized Dennis Chan with the 2020 National Citizen Scientist Catalyst Award! Dennis is a volunteer in the A4 #Alzheimers prevention trial and was inspired to join by his children. Read his story here: https://globalalzplatform.org/2020/10/22/westford-retiree-receives-national-award-for-alzheimers-volunteerism/
October 15, 2020
The Massachusetts Alzheimer's Disease Research Center (MADRC) is pleased to announce an opening for a two-year Clinical Fellowship in Dementia at the Massachusetts General Hospital (MGH) and related institutions beginning .
The goal of the non-degree program is to introduce exceptionally-qualified individuals to the successes and demands of a clinical career in dementia and related neurodegenerative diseases, and to provide an unparalleled foundation for potential leadership roles in academic medicine, industry or related fields.
More information is attached.
Fellowship application deadline: July 1, 2021
September 22, 2020
Are you having problems with your memory and thinking abilities or concerned about recent changes? Do you have a family history of Alzheimer’s disease (AD)? Have you recently received a diagnosis of AD? Consider participating in the Clarity AD clinical trial. This study will assess the safety, tolerability, and effectiveness of a new investigational medication to determine if it will stop or reduce the amount of amyloid in the brain (a protein that can build up in the brain of individuals with AD) and evaluate if it will stop or slow the progression of symptoms in individuals living with early Alzheimer’s disease. For more information click on the attached flyer.
September 21, 2020
The Massachusetts Alzheimer’s Disease Research Center (MADRC) is pleased to announce a Call for development research project proposals on Alzheimer’s disease (AD) and related dementias. For more information, see the attached document.
August 20, 2020
If you are new to Zoom and having trouble figuring it out, check out this great "Zoom How To" lesson put together by our friends at Michigan ADRC! See attached document.
August 13, 2020
To learn more about what the Massachusetts Travel Order means for patients and visitors, click on the attached document.
August 5, 2020
The virtual Alzheimer’s Association International Conference (AAIC) last week brought together thousands of researchers from across the globe to share their findings. We are proud of the many MADRC-affiliated staff who presented study results and theories that will help advance Alzheimer’s and related dementia research!
Attached is a list of presentations made by MADRC team members* at AAIC (*in red).
August 5, 2020
Congratulations to Dr. Brad Dickerson who was recently promoted to Professor of Neurology at Harvard Medical School! Dr. Dickerson is the MGH Tommy Rickles Endowed Chair in Primary Progressive Aphasia Research, Director of the Frontotemporal Disorders Unit, and Leader of the Alzheimer Center Imaging Core. He has been an NIH-funded investigator continuously for more than 17 years and has over 195 peer-reviewed publications.
To learn more about Dr. Dickerson’s work: http://www.dickersonlab.org
July 28, 2020
Dr. Yakeel T. Quiroz received the Inge-Grundke-Iqbal Award for Alzheimer’s Research at the Alzheimer's Association International Conference underway this week! This award is presented to the senior author of the most impactful study published in Alzheimer’s research during the two calendar years preceding AAIC.
Dr. Quiroz is an Associate Professor in the Departments of Psychiatry and Neurology at Massachusetts General Hospital, Harvard Medical School, Director of the MGH Familial Dementia Neuroimaging Lab, and Director of the Multicultural Alzheimer’s Prevention Program (MAPP). She received the award for her investigation into the role of APOE3 Christchurch (R136S) mutation in the resistance to autosomal dominant Alzheimer’s disease. Her research group recently identified a PSEN1 mutation carrier who did not develop mild cognitive impairment until three decades after the expected age of onset. Additionally, this individual was found to carry two copies of the APOE3 Christchurch mutation, and had unusually high brain amyloid levels and limited tau and neurodegenerative measurements.
Dr. Quiroz’s findings, “Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report,” were published in Nature Medicine in 2019, and provide important insights into the role of this APOE mutation in neurodegeneration and clinical onset of Alzheimer’s disease dementia.
July 23, 2020
Interested in participating in research but wondering about the differences between clinical trials and observational studies? This graphic helps explain the difference: